Open AccessHigh Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
Author(s) -
Hu Zhang,
Daniel Frendl,
Zongwei Wang,
Aria F. Olumi
Publication year - 2020
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000001014
Subject(s) - medicine , 5 alpha reductase inhibitor , alpha (finance) , hyperplasia , medication adherence , urology , gynecology , intensive care medicine , prostate , surgery , finasteride , patient satisfaction , cancer , construct validity
Although clinical trials demonstrate 5-alpha reductase inhibitors are efficacious treatments for benign prostatic hyperplasia, they have low reported medication adherence outside of clinical trials. We evaluated real-world drug adherence and clinical outcomes in Medicare patients with lower urinary tract symptoms from benign prostatic hyperplasia managed with 5-alpha reductase inhibitor therapy.